Daily transcutaneous tibial nerve stimulation to improve bladder emptying in multiple sclerosis
Official title: Efficacy and Safety of Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis Patients.
Run by University Hospital, Lille · NCT04573673 · Data updated 2026-11-12
This trial will test whether daily transcutaneous tibial neurostimulation for 30 minutes over 12 weeks can improve bladder emptying in people with multiple sclerosis who use clean intermittent self-catheterization.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 68 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Status | Recruiting |
| Started | December 1, 2021 |
| Main results expected | June 2026 |
| Study ends | June 2026 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT04573673 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with multiple sclerosis and bladder-sphincter dyssynergia who rely exclusively on clean intermittent self-catheterization, have EDSS below 6, and have not recently received tibial stimulation, sacral neuromodulation, or botulinum toxin A.
✕Probably not a fit
Patients with other neurological diseases, EDSS ≥ 6, recurrent urinary tract infections, uncontrolled detrusor overactivity or bladder compliance disorders, recent tibial or sacral neuromodulation, or recent botulinum toxin or alpha-blocker treatment are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with multiple sclerosis and bladder-sphincter dyssynergia who empty their bladder using clean intermittent self-catheterization are randomized to receive either active transcutaneous tibial neurostimulation or a placebo (no current) for 30 minutes daily over 12 weeks. The primary outcome is change in bladder voiding efficiency (BVE ratio) measured 12 weeks after randomization. Safety and tolerability are monitored during the treatment period. The control arm follows the same schedule with sham stimulation to blind participants.
Why it matters
Potential benefit: If successful, the treatment could improve bladder emptying and reduce incomplete voiding for people with MS who use self-catheterization.
How similar studies have gone: Tibial nerve stimulation and percutaneous tibial nerve stimulation have shown benefit for overactive bladder in prior studies, but evidence specifically for improving voiding dysfunction in MS patients is limited and mixed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with a diagnosis of multiple sclerosis * Patient with bladder-sphincter dyssinergia * Patient using clean intermittent self-catheterization as exclusive bladder management * Patient who has given written consent * Socially insured patient * Patient willing to comply with all study procedures and study duration Exclusion Criteria: * Patient with other associated neurological pathology * Patient with an Expanded Disability Status Scale (EDSS) score ≥ 6 * Patient with recurrent urinary tract infections (\> 3 episodes / year) * Patient with uncontrolled overactive bladder * Patient with uncontrolled detrusor hyperactivity * Patient with a bladder compliance disorder * Patient with tibial neuro-stimulation in the last 3 months * Patient treated with a sacral neuro-modulation * Patient who has received an intradermal injection of botulinum toxin A within the last 9 -months Patient who received alpha-blocker treatment within the last month Patient with benign prostatic hypertrophy (prostate volume \> 40 cc) - Last ultrasound scan \< 6 months. Patient with one or more bladder diverticulum(s) Patient with unilateral or bilateral renal Patient with unilateral or bilateral vesico-ureteral reflux Patient with impaired renal function (GFR according to CKD-EPI \< 60 ml/min/1.73m2) Patient with a metallic prosthesis on the lower limb Patient with a Pacemaker Pregnant patient
Where it's running
-
Hop Claude Huriez Chu Lille
Lille, France Recruiting
Study contacts
- Principal investigator: Xavier Biardeau, MD — University Hospital, Lille
- Study coordinator: Xavier Biardeau, MD
- Email: xavier.biardeau@chru-lille.fr
- Phone: 03.20.44.41.73
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effect of stem cell transplantation on urinary function in MS patients
This study looks at whether stem cell transplantation can improve urinary problems and quality of life for people with multiple sclerosis compared to those receiving other treatments.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.